References
- Klein EA, Yousefi K, Haddad Z, Choeurng V, Buerki C, Stephenson AJ, Davicioni E. A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy. Eur Urol. 2015;67(4):778–786.
- Peters M, Moerland MA, Hoekstra CJ, van de Pol S, Westendorp H, Maenhout M, Shah TT. Multivariable model development and internal validation for prostate cancer specific survival and overall survival after whole-gland salvage Iodine-125 prostate brachytherapy. Radiother Oncol. 2016;119(1):104–110.
- Yang KF, Lee HY, Wu WJ, Huang CH, Chou YH, Huang CN, Huang SP. Prediction for survival following docetaxel-based chemotherapy in Taiwanese men with castration-resistant metastatic prostate cancer. Urol Sci. 2015;26(4):271–276.
- Nennecke A, Geiss K, Hentschel S, Vettorazzi E, Jansen L, Eberle A, GEKID Cancer Survival Working Group. Survival of cancer patients in urban and rural areas of Germany—A comparison. Cancer Epidemiol. 2014;38(3):259–265.
- Ashrafi D, Baade P, Yaxley J, Roberts MJ, Williams S, Gardiner RA. Long-term survival outcomes for men who provided ejaculate specimens for prostate cancer research: implications for patient management. Eur Urol Focus. 2015;1(2):200–206.
- Koo KC, Park SU, Kim KH, Rha KH, Hong SJ, Yang SC, Chung BH. Predictors of survival in prostate cancer patients with bone metastasis and extremely high prostate-specific antigen levels. Prostate Int. 2015;3(1):10–15.
- Afshar M, Evison F, James ND, Patel P. Shifting paradigms in the estimation of survival for castration-resistant prostate cancer: a tertiary academic center experience. Urol. Oncol. 2015;33(8):338.
- Charvat H, Bossard N, Daubisse L, Binder F, Belot A, Remontet L. Probabilities of dying from cancer and other causes in French cancer patients based on an unbiased estimator of net survival: a study of five common cancers. Cancer Epidemiol. 2013;37(6):857–863.
- Gandaglia G, Karakiewicz PI, Briganti A, Passoni NM, Schiffmann J, Trudeau V, Sun M. Impact of the site of metastases on survival in patients with metastatic prostate cancer. Eur Urol. 2015;68(2):325–334.
- Rescigno P, Lorente D, Bianchini D, Ferraldeschi R, Kolinsky MP, Sideris S, Jayaram A. Prostate-specific antigen decline after 4 weeks of treatment with abiraterone acetate and overall survival in patients with metastatic castration-resistant prostate cancer. Eur Urol. 2016;70(5):724–731.
- Dell'Oglio P, Suardi N, Boorjian SA, Fossati N, Gandaglia G, Tian Z, Karnes RJ. Predicting survival of men with recurrent prostate cancer after radical prostatectomy. Eur J Cancer. 2016;54:27–34.
- Fizazi K, Massard C, Smith M, Rader M, Brown J, Milecki P, Damião R. Bone-related parameters are the main prognostic factors for overall survival in men with bone metastases from castration-resistant prostate cancer.Eur Urol. 2015;68(1):42–50.
- Fizazi K, Massard C, Smith M, Rader M, Brown J, Milecki P, Damião R. Bone-related parameters are the main prognostic factors for overall survival in men with bone metastases from castration-resistant prostate cancer.Eur Urol. 2015;68(1):42–50.
- Jang JS. ANFIS: adaptive-network-based fuzzy inference system. IEEE Trans Sys Man Cybernet. 1993;23(3):665–685.